FDA’s Prasugrel Presentation To Advisory Committee Eases Doubts On Approvability
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA presentation put the advisory committee at ease with prasugrel’s benefit-risk profile and may have turned the tide toward approvability.